BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 21, 2006
View Archived Issues
Gilead Buying Rest Of Corus; $365M Plus Lawsuit Payout
Just more than three months after pumping $25 million into Corus Pharma Inc., Gilead Sciences Inc. - already Corus' largest shareholder - is exercising its option to buy out the firm, at a price tag of $365 million. (BioWorld Today)
Read More
ImClone Amending Erbitux Merck KGaA Arrangement
Read More
Surprise Findings On Telomere Protection Genes, Mechanisms
Read More
Cubist Backs Off HepeX-B Due To Regulatory Issues
Read More
Clinic Roundup
Read More
Other News To Note
Read More
Appointments And Advancements
Read More